Wunderlich Securities Maintains Hold on Heartware

Wunderlich Securities is out with a research report on Heartware

and is maintaining its Hold rating and $80 price target on shares. In a note to clients, Wunderlich writes, "Heartware (

) provided an update of its ADVANCE bridge-to-transplant clinical trial Sunday during the EACTS Annual Meeting in Lisbon, Portugal. The update included data from the 140 patients in the ADVANCE trial and an additional 101 patients with at least six months of followup post implant from the Continued Access Protocol (

) allotments. The update was consisent with Heartware's June clinical update, showing reduced rates of thrombus requiring a pump exchange. The combined data suggest a thrombus rate under 5% is more likely for HVAD, which we believe will ease the concerns that arose back in April at the ISHLT meeting. We maintain our Hold rating and $80 target." Shares of HTWR are off 26 cents to $67.20.